Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.
Saved in:
| Title: | Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study. |
|---|---|
| Authors: | Humbert-Droz M; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Becker AM; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Valenta J; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Rudin D; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Luethi D; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Vukalovic I; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Eckert A; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Liechti ME; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland. matthias.liechti@usb.ch.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. matthias.liechti@usb.ch., Mueller L; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. |
| Source: | Translational psychiatry [Transl Psychiatry] 2026 Jun 04. Date of Electronic Publication: 2026 Jun 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101562664 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2158-3188 (Electronic) Linking ISSN: 21583188 NLM ISO Abbreviation: Transl Psychiatry Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
